Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

Prévost, Jérémie; Gasser, Romain; Beaudoin-Bussières, Guillaume; Richard, Jonathan; Duerr, Ralf; Laumaea, Annemarie; Anand, Sai Priya; Goyette, Guillaume; Benlarbi, Mehdi; Ding, Shilei; Medjahed, Halima; Lewin, Antoine; Perreault, Josée; Tremblay, Tony; Gendron‐Lepage, Gabrielle; Gauthier, Nicolas; Carrier, Marc; Marcoux, Diane; Piché, Alain; Lavoie, Myriam; Benoît, Alexandre; Loungnarath, Vilayvong; Brochu, Gino; Haddad, Élie; Stacey, Hannah D.; Miller, Matthew S.; Desforges, Marc; Talbot, Pierre J.; Maule, Graham T. Gould; Côté, Marceline; Therrien, Christian; Serhir, Bouchra; Bazin, Renée; Roger, Michel; Finzi, Andrés

doi:10.1101/2020.06.08.140244

Cited by 39 publications

(88 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the most striking observation comes from the comparison of the 3 rd and 4 th quartile (70 to 84 and 85 to 114 days after symptoms onset, respectively), where a marked decrease in the mean OD values (significative mean OD decrease of -0.486 from 1.321 ± 0.720 to 0.835 ± 0.670, representing a 36.8% decrease with p-value of 0.0052) and an even more pronounced decrease in median values (median OD decreases from 1.411 (IQR 1.52) to 0.411 (IQR 1.15) representing a 70.1% decrease) were observed. Altogether, these observations are in agreement with recent studies reporting a decrease in anti-RBD responses and neutralization activity in the plasma of convalescent donors a few weeks after symptoms resolution (19)(20)(21)(22) Interestingly, the decrease in mean and median OD values during a period of about 20 days (considering the mean and median of 3 rd and 4 th quartiles, both of 76 and 95 days respectively) is reminiscent of the plasma IgG half-life of 21 days (23), suggesting that de novo synthesis of anti-RBD antibodies stopped between the 3 rd and 4 th quartiles in all CCP donors. This time frame is consistent with the first wave of a humoral immune response during which short-lived plasma cells actively secrete pathogen-specific antibodies until the antigen is eliminated (24).…”

Section: Main Textsupporting

confidence: 93%

See 1 more Smart Citation

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors

Perreault

Tremblay

Fournier

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Héma-Québec, the blood supplier in the Province of Quebec, Canada, collects and tests convalescent plasma used in a clinical trial to determine the clinical efficacy of this product for the treatment of hospitalized COVID-19 patients. So far, we have collected 1159 plasma units from 282 COVID-19 convalescent donors. The presence of antibodies to the receptor binding domain (RBD) of SARS-CoV-2 spike protein in convalescent donors was established at the first donation. Seropositive donors were asked to donate additional plasma units every six days. Until now, 15 donors have donated at least four times and, in some cases, up to nine times. This allowed us to perform a longitudinal analysis of the persistence of SARS-CoV-2 RBD-specific antibodies in these repeat donors, with the first donation occurring 33-77 days after symptoms onset and donations up to 71-114 days after symptoms onset thereafter. In all donors, the level of antibodies remained relatively stable up to about 76 days after symptoms onset but then started to decrease more rapidly to reach, in some convalescent donors, a seronegative status within 100-110 days after symptoms onset. The decline in anti-RBD antibodies was not related to the number of donations but strongly correlated with the numbers of days after symptoms onset (r = 0.821). This suggests that de novo secretion of SARS-CoV-2 RBD antibodies by short-lived plasma cells stopped about 2-3 months after disease onset, an observation that has important implications for convalescent plasma collection and seroprevalence studies undertaken several months after the peak of infection.

show abstract

Section: Main Textsupporting

confidence: 93%

“…The presence of antibodies against SARS-CoV-2 RBD was determined using a semi-quantitative ELISA. The assay was adapted from a recently described protocol (20,21). The plasmid encoding for SARS-CoV-2 S RBD was synthesized commercially (Genscript).…”

Section: Sars-cov-2 Rbd Elisamentioning

confidence: 99%

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors

Perreault

Tremblay

Fournier

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…We first evaluated the presence of RBD-specific IgG and IgM antibodies by ELISA as we recently described (14). In agreement with a recent report (16), we observed that both RBDspecific IgG and IgM titers significantly decreased between 6 and 10 weeks after symptoms onset.…”

Section: Main Textsupporting

confidence: 83%

“…Moreover, in a cross-sectional study we reported that the neutralization capacity decreased between the third and the sixth week after symptoms onset (14). Since convalescent patients are generally required to wait for 14 days after recovery to start plasma donations and that they may give multiple times in the following weeks, most donations are likely to occur even later than this.…”

Section: Main Textmentioning

confidence: 95%

See 1 more Smart Citation

Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals

Beaudoin-Bussières

Laumaea

Anand

et al. 2020

Preprint

Self Cite

106

169

View full text Add to dashboard Cite

ABSTRACTIn the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to COVID-19 patients. The therapy has been deemed safe and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here we performed repeated analyses at one-month interval on 31 convalescent individuals to evaluate how the humoral responses against the SARS-CoV-2 Spike, including neutralization, evolve over time. We observed that receptor-binding domain (RBD)-specific IgG slightly decreased between six and ten weeks after symptoms onset but RBD-specific IgM decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing SARS-CoV-2 S wild-type or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after symptoms resolution.

show abstract

Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection

et al. 2021

View full text Add to dashboard Cite

Objectives This study aimed to explore the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐specific humoral responses and T‐cell responses in patients who have recovered from coronavirus disease 2019 (COVID‐19) to understand the natural protective immune responses and to facilitate the development of vaccines. Methods We conducted a combined assessment of the changes in neutralising antibody levels and SARS‐CoV‐2‐specific T‐cell responses over time in 27 patients up to 7 months after infection. Results The neutralising antibody remained detectable in 96.3% of the patients at their second visit at about 7 months post‐onset of symptoms. However, their humoral responses, including titres of the spike receptor‐binding domain IgG and neutralising antibody, decreased significantly compared with those at first clinic visit. By contrast, the proportions of spike‐specific CD4+ T cells, but not CD8+ T cells, in COVID‐19 patients after recovery were persistently higher than those in healthy controls. No significant change was observed in the proportion of spike‐specific CD4+ T cells in patients who had recovered from COVID‐19 within 7 months. Conclusion The SARS‐CoV‐2‐specific T‐cell immune responses persisted, while the neutralising antibodies decayed. Further studies are needed to extend the longevity of neutralising antibodies and to evaluate whether these T cells are sufficient to protect patients from reinfection.

show abstract

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

Cited by 39 publications

References 35 publications

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors

Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals

Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection

Contact Info

Product

Resources

About